Assembly Biosciences (NASDAQ: ASMB) revenue
Assembly Biosciences reported revenue of $72.3m for fiscal 2025, 153.5% more than in fiscal 2024 ($28.5m).
Assembly Biosciences has grown its revenue for 2 years in a row, and its best year of the last 10 was fiscal 2020. The biggest drop was in fiscal 2021, −92.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $72.3m | +153.5% | −$12.1m | −16.8% |
| 2024 | $28.5m | +298.2% | −$45.4m | −159.3% |
| 2023 | $7.2m | — | −$64.6m | −902.5% |
| 2022 | $0.0m | −100.0% | −$94.1m | — |
| 2021 | $6.3m | −92.1% | −$132.7m | −2,121.7% |
| 2020 | $79.1m | +395.6% | −$64.8m | −81.9% |
| 2019 | $16.0m | +7.8% | −$102.7m | −643.4% |
| 2018 | $14.8m | +64.1% | −$92.7m | −626.4% |
| 2017 | $9.0m | — | −$52.2m | −579.1% |
| 2016 | $0.0m | — | −$45.3m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Assembly Biosciences revenue compared with its sector
By revenue for its latest fiscal year, Assembly Biosciences ranks 310th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Assembly Biosciences, 153.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 308th | Recursion Pharmaceuticals | $74.7m | 26.9% |
| 309th | Electromed | $73.8m | 15.3% |
| 310th | Assembly Biosciences | $72.3m | 153.5% |
| 311th | Viridian Therapeutics | $70.8m | 23,359.9% |
| 312th | Codexis | $70.4m | 18.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Assembly Biosciences
- How much revenue did Assembly Biosciences make in fiscal 2025?
- Assembly Biosciences reported revenue of $72.3m for fiscal 2025, compared with $28.5m in fiscal 2024.
- What was the best year for revenue at Assembly Biosciences?
- Of its last 10 fiscal years, fiscal 2020, with $79.1m.
- Where does Assembly Biosciences rank in its sector by revenue?
- It ranks 310th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Assembly Biosciences come from?
- From the annual report (Form 10-K) that Assembly Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Assembly Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Assembly Biosciences: the Assembly Biosciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.